Close
series event

Mass Drug Administration with Ivermectin: A promising tool toward malaria elimination

 	A patient is given a does of IV and DP as part of a mass drug administration trial attempting to eradicate malaria in the region. IV (Ivemectin) kills any mosquito as it bites the patient, and the DP (Dihydroartemisinin-Piperaquine) kills the malaria parasite. Basse, The Gambia. Credit: Louis Leeson/LSHTM
A patient is given a does of IV and DP as part of a mass drug administration trial attempting to eradicate malaria in the region. IV (Ivemectin) kills any mosquito as it bites the patient, and the DP (Dihydroartemisinin-Piperaquine) kills the malaria parasite. Basse, The Gambia. Credit: Louis Leeson/LSHTM

The burden of malaria in The Gambia has substantially declined over the past two decades. However, transmission of the disease persists, especially in the eastern part of the country.  The vision of the World Health Organization and the global malaria community is a world free of malaria, with countries accelerating efforts toward elimination by combining interventions tailored to local contexts. 

Researchers at the Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine (MRCG at LSHTM) conducted the first cluster-randomised trial to assess the combined effect of mass drug administration (MDA) with ivermectin and dihydroartemisinin-piperaquine on the prevalence of Plasmodium falciparum infection and survival of malaria vectors in settings where the coverage of standard control interventions is high. 

Join us as we discuss the results of this trial and what this means for malaria in The Gambia, and elsewhere.  

Speakers 

Harouna Dit Massire Soumare, PharmD, Manager Entomology Laboratory/Project Entomologist at MRCG at LSHTM, PhD student 

Talk: Malaria vector control and transmission dynamic to inform elimination in The Gambia context 

Edgard Dabira, MD, Research Clinician and Clinical Trial Coordinator at MRCG at LSHTM, PhD candidate 

Talk: Mass drug administration of ivermectin and dihydroartemisinin-piperaquine against malaria in settings with high coverage of standard control interventions: a cluster randomised controlled trial in The Gambia 

 

Admission

Admission
Follow webinar link. Free and open to all. No registration required.

Contact

Contact
LSHTM Malaria Centre logo